CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmacy benefit manager CVS is considering a range of drugs and indications for the program, noting some oncology approvals in the coming months may be eligible.
You may also be interested in...
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.